Myostatin Inhibitors: Panacea or Predicament for Musculoskeletal Disorders?
Joonho Suh, Yun-Sil Lee
J Bone Metab. 2020;27(3):151-165.   Published online 2020 Aug 31     DOI: https://doi.org/10.11005/jbm.2020.27.3.151
Citations to this article as recorded by Crossref logo
Novel myostatin-specific antibody enhances muscle strength in muscle disease models
Hiroyasu Muramatsu, Taichi Kuramochi, Hitoshi Katada, Atsunori Ueyama, Yoshinao Ruike, Ken Ohmine, Meiri Shida-Kawazoe, Rie Miyano-Nishizawa, Yuichiro Shimizu, Momoko Okuda, Yuji Hori, Madoka Hayashi, Kenta Haraya, Nobuhiro Ban, Tatsuya Nonaka, Masaki Hon
Scientific Reports.2021;[Epub]     CrossRef
Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments
Juha J. Hulmi, Tuuli A. Nissinen, Fabio Penna, Andrea Bonetto
Cells.2021; 10(3): 516.     CrossRef
Therapeutic aspects of cell signaling and communication in Duchenne muscular dystrophy
Alicja Starosta, Patryk Konieczny
Cellular and Molecular Life Sciences.2021;[Epub]     CrossRef
Hip fracture and sarcopenia: the need for a new paradigm in drug trials for older adults?
Miles D Witham, Richard M Dodds
The Lancet Healthy Longevity.2021; 2(5): e234.     CrossRef
The Failed Clinical Story of Myostatin Inhibitors against Duchenne Muscular Dystrophy: Exploring the Biology behind the Battle
Emma Rybalka, Cara Timpani, Danielle Debruin, Ryan Bagaric, Dean Campelj, Alan Hayes
Cells.2020; 9(12): 2657.     CrossRef